Cargando…
Targeting ARID1A-Deficient Cancers: An Immune-Metabolic Perspective
Epigenetic remodeling and metabolic reprogramming, two well-known cancer hallmarks, are highly intertwined. In addition to their abilities to confer cancer cell growth advantage, these alterations play a critical role in dynamically shaping the tumor microenvironment and antitumor immunity. Recent s...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047504/ https://www.ncbi.nlm.nih.gov/pubmed/36980292 http://dx.doi.org/10.3390/cells12060952 |
_version_ | 1785013941153300480 |
---|---|
author | Lebedev, Timofey Kousar, Rubina Patrick, Bbumba Usama, Muhammad Lee, Meng-Kuei Tan, Ming Li, Xing-Guo |
author_facet | Lebedev, Timofey Kousar, Rubina Patrick, Bbumba Usama, Muhammad Lee, Meng-Kuei Tan, Ming Li, Xing-Guo |
author_sort | Lebedev, Timofey |
collection | PubMed |
description | Epigenetic remodeling and metabolic reprogramming, two well-known cancer hallmarks, are highly intertwined. In addition to their abilities to confer cancer cell growth advantage, these alterations play a critical role in dynamically shaping the tumor microenvironment and antitumor immunity. Recent studies point toward the interplay between epigenetic regulation and metabolic rewiring as a potentially targetable Achilles’ heel in cancer. In this review, we explore the key metabolic mechanisms that underpin the immunomodulatory role of AT-rich interaction domain 1A (ARID1A), the most frequently mutated epigenetic regulator across human cancers. We will summarize the recent advances in targeting ARID1A-deficient cancers by harnessing immune-metabolic vulnerability elicited by ARID1A deficiency to stimulate antitumor immune response, and ultimately, to improve patient outcome. |
format | Online Article Text |
id | pubmed-10047504 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100475042023-03-29 Targeting ARID1A-Deficient Cancers: An Immune-Metabolic Perspective Lebedev, Timofey Kousar, Rubina Patrick, Bbumba Usama, Muhammad Lee, Meng-Kuei Tan, Ming Li, Xing-Guo Cells Review Epigenetic remodeling and metabolic reprogramming, two well-known cancer hallmarks, are highly intertwined. In addition to their abilities to confer cancer cell growth advantage, these alterations play a critical role in dynamically shaping the tumor microenvironment and antitumor immunity. Recent studies point toward the interplay between epigenetic regulation and metabolic rewiring as a potentially targetable Achilles’ heel in cancer. In this review, we explore the key metabolic mechanisms that underpin the immunomodulatory role of AT-rich interaction domain 1A (ARID1A), the most frequently mutated epigenetic regulator across human cancers. We will summarize the recent advances in targeting ARID1A-deficient cancers by harnessing immune-metabolic vulnerability elicited by ARID1A deficiency to stimulate antitumor immune response, and ultimately, to improve patient outcome. MDPI 2023-03-21 /pmc/articles/PMC10047504/ /pubmed/36980292 http://dx.doi.org/10.3390/cells12060952 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Lebedev, Timofey Kousar, Rubina Patrick, Bbumba Usama, Muhammad Lee, Meng-Kuei Tan, Ming Li, Xing-Guo Targeting ARID1A-Deficient Cancers: An Immune-Metabolic Perspective |
title | Targeting ARID1A-Deficient Cancers: An Immune-Metabolic Perspective |
title_full | Targeting ARID1A-Deficient Cancers: An Immune-Metabolic Perspective |
title_fullStr | Targeting ARID1A-Deficient Cancers: An Immune-Metabolic Perspective |
title_full_unstemmed | Targeting ARID1A-Deficient Cancers: An Immune-Metabolic Perspective |
title_short | Targeting ARID1A-Deficient Cancers: An Immune-Metabolic Perspective |
title_sort | targeting arid1a-deficient cancers: an immune-metabolic perspective |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047504/ https://www.ncbi.nlm.nih.gov/pubmed/36980292 http://dx.doi.org/10.3390/cells12060952 |
work_keys_str_mv | AT lebedevtimofey targetingarid1adeficientcancersanimmunemetabolicperspective AT kousarrubina targetingarid1adeficientcancersanimmunemetabolicperspective AT patrickbbumba targetingarid1adeficientcancersanimmunemetabolicperspective AT usamamuhammad targetingarid1adeficientcancersanimmunemetabolicperspective AT leemengkuei targetingarid1adeficientcancersanimmunemetabolicperspective AT tanming targetingarid1adeficientcancersanimmunemetabolicperspective AT lixingguo targetingarid1adeficientcancersanimmunemetabolicperspective |